In Sermo's most recent COVID-19 Real Time Barometer survey, most physicians reported that they have not seen long-COVID or long-haul cases among children, however, a substantial 26% did say they have seen pediatric long-haulers, with the most common symptom manifesting as fatigue followed by headaches, cold-like symptoms, respiratory and loss of sense of smell / taste.
Long-haulers are patients who experience persistent symptoms after the typical course of the disease.
Most doctors surveyed said that long-COVID symptoms last about 1-4 weeks or 5-6 weeks. Sixty-five percent also reported that symptoms are milder and 34% said they do not linger as much in children as they do in adults, but nevertheless, 36% of physicians surveyed are somewhat concerned about the long-term health problems children may face.
Sermo's previous COVID-19 Real Time Barometer showed 65% of physicians believe that vaccinating children is essential for long-term control of COVID, but 55% of physicians also say their patients are more reluctant to vaccinate their children than themselves due to lack of long-term safety data and fear of adverse effects or allergic reactions.
Sermo's latest COVID-19 Real Time Barometer showed 42% of physicians said 10% or less of their pediatric patients were vaccinated and still caught COVID.
Close to 50% of physicians said that in their experience, it's too soon to tell if having had COVID offers any immunity to the Delta variant.
The Real Time Barometer is an observational study of the impact of the COVID-19 outbreak as reported by physicians with firsthand experience treating COVID-19 patients.
Each week, thousands of physicians provide insights on topics regarding the global health crisis. To date, Sermo has conducted over 80,000 interviews with doctors in 31 countries, including the United States, Canada, United Kingdom, France, Brazil, Russia, China, Japan, and Australia.
Sermo turns physician experience, expertise, and observations into actionable insights for the global healthcare community.
Engaging with more than 1.3m HCPs across 150 countries, the company provides physicians with a social platform and unique community that fosters impactful peer-to-peer collaboration and discussions about issues that are important to them and their patients.
Sermo offers on demand access to physicians via a suite of proprietary technology to provide business intelligence that benefits pharmaceutical, healthcare partners, and the medical community at large.
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Genprex increases sites for Acclaim-3 clinical trial
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib